Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Hikma Pharmaceuticals
(OTCPK:HKMPY)
Intraday
$46.50
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$46.50
0
[0.00%]
At close: Apr 15
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Hikma Pharmaceuticals Stock (OTC:HKMPY)
Hikma Pharmaceuticals Stock (OTC: HKMPY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, June 12, 2023
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
Vandana Singh
-
Jun 12, 2023, 10:16AM
Tuesday, March 31, 2020
Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa
Neer Varshney
-
Mar 31, 2020, 3:21AM
Tuesday, December 10, 2019
Stocks That Hit 52-Week Highs On Tuesday
Lisa Levin
-
Dec 10, 2019, 2:27PM
Thursday, April 06, 2017
UBS Likes The Tune Of Jazz Pharma's Settlement With Hikma
Benzinga
-
Apr 6, 2017, 1:45PM
Monday, March 20, 2017
Jazz Pharma Gives Shorts A Wake-Up Call After JZP-110 Study Results
Benzinga
-
Mar 20, 2017, 1:43PM
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Benzinga
-
Mar 20, 2017, 9:17AM
Wednesday, February 10, 2016
Hikma Pharmaceuticals Offering $535M Less than Earlier Offer to Acquire Boehringer Ingelheim's US Generic Drug Business
Benzinga
-
Feb 10, 2016, 4:22AM
Wednesday, March 11, 2015
Hikma Pharmaceuticals 2014 Profit Surges
Benzinga
-
Mar 11, 2015, 5:19AM
Wednesday, November 20, 2013
Hikma Signs Long Term Supply Agreement With Unilife To Enhance Delivery Of Generic Injectables
Benzinga
-
Nov 20, 2013, 8:45AM
Wednesday, March 13, 2013
Hikma Pharma Full-Year Profit Rises 19%
Benzinga
-
Mar 13, 2013, 4:43AM
